electrophoresis (Agilent Technologies, Massy, France). cRNA was prepared according to the standard Affymetrix protocol and 10 mg hybridized to GeneChip HG-U133A oligonucleotide arrays (Affymetrix, Santa Clara, CA, USA). Expression values were determined using Affymetrix MAS 5.0 software. The gene expression data are available on our website: http://amazonia. montp.inserm.fr/downloads.php.
From the 22 283 probe sets present on the U133A array, 11 434 had absolute calls defined as 'present' by the GeneChip software in at least three samples among the 18 tested, and were further retained for analysis. All expression levels values below a threshold arbitrarily chosen as the quarter of the median value across all samples were floored to this default value ( ¼ 10). The expression level of each gene was first log-transformed and median-centered before being processed. Hierarchical clustering was performed using Cluster and Treeview software packages. 5 Initial unsupervised hierarchical clustering failed to distinguish SM cases from PU cases (data not shown). This was probably due to the low proportion of genes differentially expressed in the two groups (see below). However, restricting this analysis to the 840 probe sets which showed the highest variation in expression levels among all samples resulted in a clear segregation of CLLs in two clusters: all but one SM case (CLL6-SM) were correctly classified according to their clinical stage and mutational status ( Figure 1 and Figure S1 in Supplementary Information).
To confirm these results, we used principal component analysis as a second unsupervised algorithm. This was performed on log-transformed and median-centered data from the 4150 genes with the highest variation coefficient among the 18 samples. The first two principal components, which represented 22% of the total variance, identified two clusters, which corresponded to the clinical groups except for two cases (CLL6-SM and CLL11-PU) ( Figure S2 , supplemental data). Thus, taking into account that we selected cases representing both ends of the disease spectrum and restricted the analysis to the 840 most differentially expressed genes, both unsupervised methods could distinguish the majority of SM-from PU-CLLs by their pattern of gene expression.
Supervised analysis was performed using the Mann-Whitney nonparametric statistical and calculations were performed with the SPSS software (SPSS Inc, Chicago IL, USA). Of the 11434 genes, 733 were differentially expressed among SM and PU groups (P-value o0.05). However, a 42-fold change was found for only 84 of these after exclusion of Ig genes (Tables S2 and S3 , Supplemental data). For the majority of them, the fold change was within a 2-3 range. It was above three for 32 genes, and above four for only 14 genes. PU-CLL cases overexpressed 43 genes including some previously recognized such as BCL7A, LPL (lipoprotein lipase), AKAP12 (gravin), CRY1, CLECSF2, DMD (dystrophin) and ZAP-70. In contrast with previous studies, an equivalent number of genes (n ¼ 41) were also overexpressed in SM-CLL cases, the most prominent of which were MYL9, NRIP1, FCGBP, SPRY2, TCF7 and ADAM29. Table 1 includes the 26 genes that displayed a 43-fold change and a P-value p0.01, as well as two other genes (WNT3, SPAP1) which had a slightly lower fold change (2,5 and 2,3, respectively) but were involved in pathways such as TCF7 regulation and BCR signalling.
Since the number of patients we analyzed was small, this may have led to false identification of discriminating genes, as a result of chance only. Thus, a statistical permutation permutation test was used to estimate how many genes could be expected to appear differentially expressed from random class distinction. This was made with the R environment (http:// www.r-project.org). We performed 100 permutations and determined that 1.47 out of 11 434 genes would have a ratio 43 and a P-value p0.01 in Mann-Whitney analysis by chance only.
We verified the relative expression of 18 genes by quantitative reverse-transcription polymerase chain reaction (RQ-PCR), including 16 of the 26 with a 43-fold change and a P-value p0.01, and two other genes (WNT3, SPAP1). Experiments were carried out on the same purified leukemic RNAs used for microarray hybridization, for 16 of the 18 patients for whom material was still available. Of these genes, 10 (AKAP12, ADAM29, BCL7A, CLECSF2, FCGBP, FLJ10884, FUT8, LPL, TCF7, WNT3) were quantified using Assay-on-Demand Gene Expression Probes and TaqMan reagents on an ABI Prism 7000 Sequence Detector System (all supplied by Applied Biosystems, Les Ulis, France). The other eight genes (APOD, SPG20, MYL9, NRIP1, SPAP1, SPRY2, TGFBR3, ZAP-70) were quantified by the SYBR Green I method on the Light Cycler System (Roche Molecular Biochemicals, Mannheim, Germany). Primers used in the latter cases were designed with Gene Runner software (Hastings Software, Colorado, USA) and their sequences are depicted in Table S4 (Supplementary Information). All PCR reactions were performed on cDNA from 100 ng of total RNA and done in duplicate. The housekeeping beta-glucuronidase (GUS) gene served to normalize quantitative data. Standard curves were established following serial sample dilutions to ensure that amplification efficiency within each cycle was close to a factor 2 (data not shown). The differential expression of all of tested genes was confirmed, though a higher fold change was generally found in RQ-PCR when compared to microarray experiments (Table 1 ). Figure S3 (supplemental data) depicts the distribution of patients according to differential expression of six of these genes, including ZAP-70, which displayed the best delineation of the two groups of CLLs. As previously reported, ZAP-70 expression clearly predominated among PU cases (eight out of nine). However, a higher fold change ratio between PU and SM cases was found for LPL, FLJ10884, and SPG20. In addition, two previously unrecognized discriminating genes, ADAM29 and NRIP1, strongly distinguished SM (both overexpressed in six of seven cases) from PU cases (both underexpressed in eight of nine cases).
In agreement with previous reports 2, 3 our results demonstrate that less than 1% of transcribed genes in CLL B-cells were significantly and differentially expressed in SM and PU patients, thus supporting the single disease hypothesis. However, in contrast with these previous studies, two independent unsupervised analytical methods succeeded in distinguishing indolent from aggressive forms of the disease. This could be accounted 
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for by the different patient inclusion criteria, the cell purification procedure (negative vs positive selection), and the fact that we used a more recent version of the Affymetrix DNA chip, which includes a higher number of gene probes than that employed in previous reports. The same explanations may apply to the fact that the majority of the genes that we identified as differentially expressed have not been previously reported by studies comparing CLL upon their Ig mutational status. Thus, only seven genes were in common with those described in Klein's report, 2 six with that of Rosenwald et al. 3 Our data suggest that CLL may be considered as a single disease with at least two variants that differ in their clinical course and Ig mutational status. It is clear, however, that this view is a simplification and that reality is more complex. For instance two patients in this series clustered in the opposite group. This indicates that other factors than the clinical stage and Ig mutational status, such as chromosome abnormalities for instance, may impact on the global gene expression profile. Haslinger et al 6 reported recently that gene expression profiles of B-CLL depend on genomic alterations. Unfortunately, the number of cases with distinct genetic abnormalities in our series was not sufficient to draw firm conclusions in this direction.
The mutational status of Ig is one of the most robust biological prognostic indicators in CLL. However, defining Ig gene sequence is not suitable for routine purposes. These considerations have made finding a surrogate for Ig mutational status in CLL an important priority. Following microarray studies reporting that ZAP-70 overexpression in Ig-unmutated CLLs, 3 its detection by a simple and convenient multiparameter flow-cytometric test has recently been shown to be highly correlated to the presence of an Ig unmutated status. 7 Our microarray data, confirmed by RQ-PCR studies, show that other genes such as LPL, FLJ10884, SPG20, might be as discriminative as ZAP-70. In addition, ADAM29 and NRIP1 are potentially good predictors for SM patients. We have very recenly evaluated the capacity of some of these genes to predict clinical outcome in an independent series of 127 CLL patients. 8 Our data show that the quantification of LPL and ADAM29 mRNAs constitutes a reliable surrogate of the Ig mutational profile and provides strong prognosis information Finally, we tried to correlate possible functions and interactions for these differentially expressed genes, according to a literature search. We focused our attention on the 28 genes which had a 43-fold change ratio with a Pp0.01 and/or whose differential expression had been validated by RQ-PCR. As a result of this relatively limited set of genes, we attempted to integrate their physiological properties into a schematic representation ( Figure S4 in Supplementary Information). The main emerging features are the role of the B-cell receptor (BCR) activation pathway, cytoskeletal regulation and interactions with the extracellular matrix. Although these considerations are so far hypothetical, they point out new directions for further functional studies.
In summary, our study shows that gene expression profiling can differentiate SM-from PU-CLLs. It identified new genes which expression level monitoring can serve as prognostic indicators. It also points out some of the potential pathways involved in the different biological and clinical patterns of the disease. If confirmed at the protein level, this may provide new molecular clues for pharmaceutical targeting. Some cases of T-LGL are complicated by severe anemia due to pure red cell aplasia (PRCA). 3 PRCA is believed to result from expansion of cytotoxic lymphocytes and is also treated with immunosuppressive therapy including corticosteroids, cyclophosphamide and CSA. Recently, successful therapy of two refractory cases of PRCA with standard doses of anti-CD52 monoclonal antibody (alemtuzumab) has been reported. 4 So far, one patient with T-LGL has been reported who responded to alemtuzumab. 5 In this case, standard doses of Campath-1H were associated with considerable toxicity. 5 Hematologic side effects of alemtuzumab may sometimes require treatment withdrawal. 6 In a recent article published in this journal, Laurenti et al 7 reported rapid immune recovery after low-dose Campath-1H in a group of heavily pretreated patients affected by B-CLL.
Case report
Here, we report successful treatment of pure red cell aplasia with low-dose alemtuzumab in a patient with T-cell receptor gdlarge granular lymphocyte leukemia (TLGLgd) refractory to CSA and MTX treatment. The patient was an 84-year-old Caucasian medical doctor, who was first diagnosed to have T-LGL in June 2003. Over the preceding 9 months, he had experienced a
